Heron Therapeutics Inc Stock Price, News & Analysis

Welcome to our dedicated page for Heron Therapeutics news (Ticker: HRTX), a resource for investors and traders seeking the latest updates and insights on Heron Therapeutics stock.

Heron Therapeutics, Inc. (Nasdaq: HRTX) is a commercial-stage biotechnology company whose news flow is closely tied to its acute care and oncology supportive care portfolio. The company regularly issues updates on its marketed products ZYNRELEF, APONVIE, CINVANTI, and SUSTOL, as well as financial and corporate developments that affect HRTX stock.

On this page, readers can follow HRTX news related to quarterly and annual financial results, net revenue trends by product, and guidance updates disclosed in earnings press releases. Heron’s announcements often break out performance for its Acute Care franchise, which includes ZYNRELEF for postoperative pain and APONVIE for prevention of postoperative nausea and vomiting in adults, and its Oncology franchise, which includes CINVANTI and SUSTOL for prevention of chemotherapy-induced nausea and vomiting.

Company news also covers regulatory and clinical milestones for Heron’s products. Examples from past releases include FDA approvals and label expansions for ZYNRELEF in various soft tissue and orthopedic surgical procedures, and recognition of APONVIE in consensus guidelines for the management of postoperative nausea and vomiting. These items help investors and clinicians track how product indications and clinical positioning evolve over time.

In addition, Heron reports capital markets and governance events through press releases and corresponding SEC filings. Recent topics have included comprehensive capital restructuring, new credit facilities and convertible note transactions, adoption of a Tax Benefit Preservation Plan to protect net operating loss carryforwards, and Board-level changes such as cooperation agreements with investors and director appointments. For users monitoring HRTX, this news feed offers a consolidated view of operational, financial, regulatory, and governance developments that the company has publicly disclosed.